The real vaccine crisis isn’t about J&J or AstraZeneca
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
MONDAY, MAY 23, 2022
MONDAY, MAY 23, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The real vaccine crisis isn’t about J&J or AstraZeneca

Panorama

David Fickling, Bloomberg
20 April, 2021, 02:30 pm
Last modified: 20 April, 2021, 02:32 pm

Related News

  • Covax calls for urgent action to close vaccine equity gap
  • Cholera inoculation in Dhaka starting first week of May
  • Corruption allegation over vaccine has no evidence: Ahmad Kaikaus
  • 23 lakh citizens to get cholera vaccine in Dhaka from May
  • Meningitis vaccine protects against gonorrhoea: Studies

The real vaccine crisis isn’t about J&J or AstraZeneca

One of the most serious Covid-era challenges the world will face is the unequal distribution of vaccines between rich and poor countries

David Fickling, Bloomberg
20 April, 2021, 02:30 pm
Last modified: 20 April, 2021, 02:32 pm
Poor countries deserve a shot. Photo: Bloomberg
Poor countries deserve a shot. Photo: Bloomberg

To judge by the headlines, you'd think the most critical immunization issue facing the world is the safety and hesitancy concerns over the AstraZeneca Plc and Johnson & Johnson vaccines.

That debate is genuinely important. Still, it shouldn't distract from the biggest challenge the world will face over the coming months: the grossly unequal distribution of vaccines between rich and poor countries.

The development and ramp-up of preventive medicine for the coronavirus is a testament to the innovative power of the modern global economy. Counting only drugs that are already on the market, total manufacturing capacity this year should be sufficient to deliver 12 billion doses, according to a database compiled by the Duke Global Health Innovation Center.

In theory, that might be enough to bring the Covid-19 pandemic to an end. With single-shot vaccines making up 1.5 billion of those doses, that could deliver enough shots to immunize about 88% of the world's population.

It's a less rosy picture when you look at how many injections have actually been booked. So far there have been orders for just 6.96 billion doses, enough to achieve about 53% coverage globally, according to the Duke database. Even those are grossly skewed toward rich countries: While there's sufficient medicine on order to fully immunize the population of high-income nations nearly two times over, in the lower middle-income ones, where the largest slice of the world's population lives, coverage falls to just 12%.

That's a familiar problem. Every drug maker in the world (even generics manufacturers, often treated as tribunes of the global south) wants to sell to rich countries, where the profit margins are highest. In the 1990s and early 2000s, HIV was ravaging sub-Saharan Africa just as the newly formed World Trade Organization was hammering out global regulations on the treatment of intellectual property. The question of pharmaceutical companies' obligation to distribute their products sparked major reforms.

In theory, the setup that resulted ought to ensure equal access to medicines around the world. Countries that fail to strike affordable licensing deals with global pharmaceutical companies can essentially annul their patents, in a process known as compulsory licensing, so that local generic drugmakers can produce their own versions. Those that lack the manufacturing capacity can even buy medicines from other countries, such as India.

In practice, the system isn't working. Compulsory licensing is barely invoked for new drugs these days. When it is, many of the instances in recent years have involved relatively wealthy countries using the framework as a tool to bargain down drug prices, rather than lower-income nations facing an absolute shortage of affordable supply.

The parameters under which compulsory licensing operates are slow and cumbersome, requiring rounds of negotiations between governments and pharmaceutical companies, and matching licenses by importing and exporting governments. Since such licenses are typically issued in defiance of the original developer, they usually depend on the ability of generics manufacturers to reverse-engineer the medicines, often without access to essential trade secrets. That's a challenge wherever cutting-edge technology is being used, especially given the short timescales involved and the need for rapid safety approvals.

The situation we're left with is failing the world. A 2016 study found that it typically takes between four years and seven years for medicines to be approved in sub-Saharan Africa from the point when the first regulatory steps are taken in rich countries.

While Covid has inspired regulatory shortcuts, such as the Covax program to speed access to vaccines in low-income countries, the slow pace of deliveries outside of the wealthiest nations is grossly inadequate. That's especially the case as the center of gravity of infections moves from rich nations and large emerging economies to a host of smaller countries less able to scale up domestic drug manufacturing.

The best hope for a breakthrough comes from the WTO's new director-general Ngozi Okonjo-Iweala, a former head of the United Nations-backed vaccine delivery partnership, who brought pharmaceutical companies, politicians and public health officials together in Geneva last week to find a solution.

U.S. Trade Representative Katherine Tai promised at the conference to "learn from, and not repeat, the tragedies and mistakes of the past." Those words must now be put into action. One immediate solution — still being blocked by the governments of rich countries, including the U.S. — would be a temporary waiver of the so-called TRIPS rules that govern trade in intellectual property. Such a waiver could be limited to Covid treatments and for the duration of the current public health emergency.

Beyond that, though, we need to recognize that the aspiration of a global trading system that would balance intellectual property protection with the health needs of all humanity has fallen short.

The best hope for a breakthrough comes from the WTO's new director-general Ngozi Okonjo-Iweala, a former head of the United Nations-backed vaccine delivery partnership, who brought pharmaceutical companies, politicians and public health officials together in Geneva last week to find a solution.

David Fickling
David Fickling

U.S. Trade Representative Katherine Tai promised at the conference to "learn from, and not repeat, the tragedies and mistakes of the past." Those words must now be put into action. One immediate solution — still being blocked by the governments of rich countries, including the U.S. — would be a temporary waiver of the so-called TRIPS rules that govern trade in intellectual property. Such a waiver could be limited to Covid treatments and for the duration of the current public health emergency.

Beyond that, though, we need to recognize that the aspiration of a global trading system that would balance intellectual property protection with the health needs of all humanity has fallen short.

Features / Top News

Vaccine / AstraZeneca / J&J

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • BPC hunts for dollar to import fuel oil
    BPC hunts for dollar to import fuel oil
  • Representational Image. Photo: Mumit M/TBS
    Govt to list products to suspend imports amid dollar crisis
  • Infographic: TBS
    With 2 months left, 45% ADP fund still unspent 

MOST VIEWED

  • Why everybody wants to be like TikTok
    Why everybody wants to be like TikTok
  • Illustration: TBS
    How the ban on porn sites spawned a local cybersex industry
  • Photo: Courtesy
    Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh
  • The Buffalo shooter targeted Black people, linking mass migration with environmental degradation and other eco-fascist ideas. Photo: Reuters
    Eco-fascism: The greenwashing of the far right
  • Green-backed Heron on a tilting stalk. Photo: Enam Ul Haque
    Green-backed Heron: Nothing but a prayer to catch a fish  
  • Illustration: TBS
    ‘High logistics cost weakens Bangladesh’s competitiveness’

Related News

  • Covax calls for urgent action to close vaccine equity gap
  • Cholera inoculation in Dhaka starting first week of May
  • Corruption allegation over vaccine has no evidence: Ahmad Kaikaus
  • 23 lakh citizens to get cholera vaccine in Dhaka from May
  • Meningitis vaccine protects against gonorrhoea: Studies

Features

Why everybody wants to be like TikTok

Why everybody wants to be like TikTok

13h | Panorama
Illustration: TBS

How the ban on porn sites spawned a local cybersex industry

16h | Panorama
3 best affordable sunscreens for all

3 best affordable sunscreens for all

16h | Mode
Warah uses three types of khadi material: a sheer and light one, a medium count and a thicker one.

Warah: Embroidered with culture and womanhood

18h | Mode

More Videos from TBS

Investors, public to suffer from electricity price hike

Investors, public to suffer from electricity price hike

5h | Videos
Health benefits of summer fruits

Health benefits of summer fruits

7h | Videos
The way Bangladesh saves almost extinct fish

The way Bangladesh saves almost extinct fish

7h | Videos
Padma’s Char now largest grazing-ground

Padma’s Char now largest grazing-ground

7h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

4
Bangladesh at risk of losing ownership of Banglar Samriddhi
Bangladesh

Bangladesh at risk of losing ownership of Banglar Samriddhi

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab